Peter Atadja

Peter Atadja is currently the Chief Scientific Officer at CommBio Therapeutics Co., Ltd. He previously worked at Novartis Pharmaceuticals Corp.
as the Executive Director & Head-Drug Discovery from 1997 to 2021.
Additionally, he served as an Independent Director at Traws Pharma, Inc. from 2022 to 2024.
Dr. Atadja also held the position of Chief Scientific Officer at K36 Therapeutics, Inc. in the past.
He holds a doctorate degree from the University of Calgary, a graduate degree from The Hebrew University of Jerusalem, and an undergraduate degree from Kwame Nkrumah University of Science & Technology.